The performance of companies tied to Viagra's legacy presents a challenging investment scenario . While the initial surge generated substantial returns , generic alternatives have significantly impacted sales . Investing in associated pharmaceutical firms now requires a discerning assessment of patent safeguards, evolving medical shifts , and the p